Last reviewed · How we verify
Bezlotoxumab Injection [Zinplava]
Inhibits Clostridioides difficile toxin
Inhibits Clostridioides difficile toxin Used for Prevention of Clostridioides difficile infection recurrence.
At a glance
| Generic name | Bezlotoxumab Injection [Zinplava] |
|---|---|
| Sponsor | Fundacion SEIMC-GESIDA |
| Drug class | Monoclonal antibody |
| Target | Clostridioides difficile toxin |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
Bezlotoxumab is a monoclonal antibody that targets and neutralizes Clostridioides difficile toxins A and B, preventing them from causing disease.
Approved indications
- Prevention of Clostridioides difficile infection recurrence
Common side effects
- Nausea
- Diarrhea
- Abdominal pain
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bezlotoxumab Injection [Zinplava] CI brief — competitive landscape report
- Bezlotoxumab Injection [Zinplava] updates RSS · CI watch RSS
- Fundacion SEIMC-GESIDA portfolio CI